Sugi Predict

Sugi Predict / Compounds / SCHEMBL8264188

SCHEMBL8264188

SCHEMBL8264188

Cc1cccc(CN(C(=O)[C@H]2CN(C(=O)OC(C)(C)C)CC[C@@H]2c2cccc(-c3ccccc3)c2)C2CC2)c1C

nearest known ligand 0.46

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ TACR1 P25103 3/20 0.46
▸ USP30 Q70CQ3 9/20 0.43
▸ REN P00797 1/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ JAK2 O60674 1/20 0.41
▸ JAK1 P23458 1/20 0.41
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ GPR119 Q8TDV5 3/20 0.37
▸ HSD11B1 P28845 1/20 0.37
▸ KAT7 O95251 1/20 0.37
▸ KAT8 Q9H7Z6 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8265069 0.95 TACR1 (0.41) TACR1USP30RENCYP3A4JAK2
SCHEMBL8263725 0.94 GPR119 (0.43) TACR1USP30RENCYP3A4JAK2
SCHEMBL8265387 0.94 TACR1 (0.42) TACR1USP30RENCYP3A4JAK2
SCHEMBL8265393 0.93 USP30 (0.43) TACR1USP30RENCYP3A4JAK2
SCHEMBL8264209 0.92 TACR1 (0.45) TACR1USP30RENJAK2JAK1
SCHEMBL8266141 0.91 TACR1 (0.47) TACR1USP30RENJAK2JAK1
SCHEMBL8265950 0.91 USP30 (0.42) TACR1USP30RENCYP3A4JAK2
SCHEMBL10183686 0.91 GPR119 (0.46) TACR1USP30RENCYP3A4GPR119
SCHEMBL8264309 0.91 TACR1 (0.45) TACR1USP30RENCYP3A4JAK2
SCHEMBL13576859 0.91 TACR1 (0.45) TACR1USP30RENCYP3A4JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178559-B2 Organic compounds NOVARTIS AG (CH) 2012-05-15 — — US disclosed
US-8178559-B2 Organic compounds NOVARTIS AG (CH) 2012-05-15 — — US disclosed
US-8084450-B2 Organic compounds NOVARTIS AG (CH) 2011-12-27 — — US disclosed
US-8084450-B2 Organic compounds NOVARTIS AG (CH) 2011-12-27 — — US disclosed
US-20110263560-A1 Organic Compounds NOVARTIS AG (CH) 2011-10-27 — — US disclosed
US-20110263560-A1 Organic Compounds NOVARTIS AG (CH) 2011-10-27 — — US disclosed
EP-2177518-A1 Organic compounds Novartis AG (CH) 2010-04-21 — — EP disclosed
US-20090312304-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-12-17 — — US disclosed
US-20090312304-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-12-17 — — US disclosed
EP-1833816-B1 SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS NOVARTIS AG (CH) 2009-11-11 — — EP disclosed
WO-2006069788-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2006-07-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263560-A1 Organic Compounds REN, ACE, OTC TACR1 433/4885USP30 3528/4885REN 1/4885
US-20090312304-A1 ORGANIC COMPOUNDS REN, ACE, PIGO TACR1 475/4885USP30 3470/4885REN 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.